Bottle Label 75 mg (71610 0677 30)
Pregabalin Capsule
Product Images NDC 71610-677
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-677). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
Figure 1 (Pregabalin Fig01)
Figure 2 (Pregabalin Fig02)
This appears to be a chart showing the percent improvement in pain from a baseline for patients taking Pregabalin 160 mg for three days. The chart includes some numerical values for improvement and time frames but is incomplete and difficult to interpret without additional context.*
Figure 3 (Pregabalin Fig03)
This appears to be a chart showing the percentage of patients who reported improvement in pain from baseline after taking different medications including Pregatalin 300, Pregabain 160, and Pregabalin 75. However, the formatting is not clear and there are some unreadable characters.*
Figure 4 (Pregabalin Fig04)
Figure 5 (Pregabalin Fig05)
The text seems to represent the result of a clinical trial for pain management, comparing two medications and a placebo. However, due to a high number of errors and lack of context, it is difficult to provide a detailed description of the trial and its outcomes.*
Figure 6 (Pregabalin Fig06)
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
This is a chart showing the percentage of patients who experienced improvement in pain from their baseline using either a daily dose of Pregabalin 300mg or 450mg and a placebo. The results are shown on a scale from 0 to 100, along with corresponding levels of percent improvement in pain.*
Figure 10 (Pregabalin Fig09)
This data shows the estimated percentage of subjects without LTR (loss to follow-up) over a 120-day period. The study includes two groups: one receiving "Progabain" and one receiving "Placebo". The percentages range from 0% to 100% with increments of 10%. The X-axis represents the number of days in the study (ranging from day 0 to day 120).*
Figure 11 (Pregabalin Fig10)
Figure 12 (Pregabalin Fig11)
The data represents the percentage of subjects who showed improvement after taking Pregabalin and Placebo for 16 weeks. The percentage of improvement is shown on the vertical axis and ranges from 0 to 100. The horizontal axis shows the values 210 through 270 in increments of 10. The improvement of Pregabalin is represented by the blue line while the improvement of Placebo is represented by the orange line. The graph is a bar chart and shows that Pregabalin resulted in a higher percentage of improvement than Placebo.*
Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a medical formula for calculating the CLCT (Creatinine clearance test) using age, weight, and serum creatinine levels. However, some characters are not readable, rendering the formula incomplete and difficult to interpret accurately.*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
